Jean-Ehrland RICCI
@jer-06.bsky.social
INSERM research director & metabolism-lover, studying metabolism in cancer & immunity, Nice, France.
Editor-in-Chief of Oncogenesis www.nature.com/oncsis
#cancermetabolism #immunometabolism #mitophagy #CAR-T - www.c3m-nice.fr/en/Teams/team-03/
Editor-in-Chief of Oncogenesis www.nature.com/oncsis
#cancermetabolism #immunometabolism #mitophagy #CAR-T - www.c3m-nice.fr/en/Teams/team-03/
Reposted by Jean-Ehrland RICCI
Check how their findings suggest that P4HB could serve not only as a potential therapeutic target for glioblastoma but also as a biomarker for auxiliary diagnosis and monitoring of disease progression.
November 27, 2025 at 10:03 AM
Check how their findings suggest that P4HB could serve not only as a potential therapeutic target for glioblastoma but also as a biomarker for auxiliary diagnosis and monitoring of disease progression.
Reposted by Jean-Ehrland RICCI
“P4HB maintains Wnt-dependent stemness in glioblastoma stem cells as a precision therapeutic target and serum marker”
🔵 Jinlong Yin impressive research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Jinlong Yin impressive research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 27, 2025 at 10:02 AM
“P4HB maintains Wnt-dependent stemness in glioblastoma stem cells as a precision therapeutic target and serum marker”
🔵 Jinlong Yin impressive research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Jinlong Yin impressive research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how PANX1 triggers rhabdomyosarcoma cell fusion by downregulating APOBEC2 expression, forcing these undifferentiated malignant cells further into the myogenic pathway, offering therapeutic potential by limiting malignant progression.
November 25, 2025 at 11:05 AM
Check how PANX1 triggers rhabdomyosarcoma cell fusion by downregulating APOBEC2 expression, forcing these undifferentiated malignant cells further into the myogenic pathway, offering therapeutic potential by limiting malignant progression.
Reposted by Jean-Ehrland RICCI
“Pannexin 1 induces Rhabdomyosarcoma cell fusion by downregulating APOBEC2”
🔵Kyle N. Cowan’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵Kyle N. Cowan’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 25, 2025 at 11:05 AM
“Pannexin 1 induces Rhabdomyosarcoma cell fusion by downregulating APOBEC2”
🔵Kyle N. Cowan’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵Kyle N. Cowan’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study provides novel mechanistic insights into the role of LUBAC in regulating HIF1α homeostasis, tumor angiogenesis and tumorigenesis of lung cancer, making LUBAC an attractive therapeutic target for cancers.
November 20, 2025 at 8:21 AM
Check how this study provides novel mechanistic insights into the role of LUBAC in regulating HIF1α homeostasis, tumor angiogenesis and tumorigenesis of lung cancer, making LUBAC an attractive therapeutic target for cancers.
Reposted by Jean-Ehrland RICCI
“LUBAC promotes angiogenesis and lung tumorigenesis by ubiquitinating and antagonizing autophagic degradation of HIF1α”
🔵 Interesting research led by Jian Fuhas was featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Jian Fuhas was featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 20, 2025 at 8:21 AM
“LUBAC promotes angiogenesis and lung tumorigenesis by ubiquitinating and antagonizing autophagic degradation of HIF1α”
🔵 Interesting research led by Jian Fuhas was featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Jian Fuhas was featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study uncovers a novel key pathway that drives renal cell carcinoma invasion and metastasis, offering a promising therapeutic target for clinical intervention.
November 18, 2025 at 9:30 AM
Check how this study uncovers a novel key pathway that drives renal cell carcinoma invasion and metastasis, offering a promising therapeutic target for clinical intervention.
Reposted by Jean-Ehrland RICCI
“SLC6A19-mediated tryptophan uptake suppresses renal cell carcinoma metastasis via activating NAD+-dependent deacetylase SIRT1”
🔵 Changwei Ji’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Changwei Ji’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 18, 2025 at 9:30 AM
“SLC6A19-mediated tryptophan uptake suppresses renal cell carcinoma metastasis via activating NAD+-dependent deacetylase SIRT1”
🔵 Changwei Ji’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Changwei Ji’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.
November 13, 2025 at 8:40 AM
Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.
Reposted by Jean-Ehrland RICCI
“MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma”
🔵 Groundbreaking research led by Carol J. Thielehas been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Groundbreaking research led by Carol J. Thielehas been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 13, 2025 at 8:39 AM
“MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma”
🔵 Groundbreaking research led by Carol J. Thielehas been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Groundbreaking research led by Carol J. Thielehas been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.
November 11, 2025 at 10:41 AM
Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.
Reposted by Jean-Ehrland RICCI
“NFATc1-mediated activation of the pentose phosphate pathway and cell cycle dysregulation collectively drive tumor progression”
🔵 Can Huang’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Can Huang’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 11, 2025 at 10:41 AM
“NFATc1-mediated activation of the pentose phosphate pathway and cell cycle dysregulation collectively drive tumor progression”
🔵 Can Huang’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Can Huang’s latest research is now available to read in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.
November 7, 2025 at 9:53 AM
Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.
Reposted by Jean-Ehrland RICCI
“EPHA5 promotes cell proliferation and inhibits apoptosis in Follicular Thyroid Cancer via the STAT3 signaling pathway”
🔵 Interesting research led by Yongfu Zhao has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Yongfu Zhao has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
November 7, 2025 at 9:53 AM
“EPHA5 promotes cell proliferation and inhibits apoptosis in Follicular Thyroid Cancer via the STAT3 signaling pathway”
🔵 Interesting research led by Yongfu Zhao has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Yongfu Zhao has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.
November 4, 2025 at 8:02 AM
Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.
Reposted by Jean-Ehrland RICCI
"Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis"
🔵 Jessica Silva-Fisher latest and outstanding research is now available to read in #Oncogenesis.
▶️ Read the open access article here: www.nature.com/articles/s41...
🔵 Jessica Silva-Fisher latest and outstanding research is now available to read in #Oncogenesis.
▶️ Read the open access article here: www.nature.com/articles/s41...
November 4, 2025 at 8:02 AM
"Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis"
🔵 Jessica Silva-Fisher latest and outstanding research is now available to read in #Oncogenesis.
▶️ Read the open access article here: www.nature.com/articles/s41...
🔵 Jessica Silva-Fisher latest and outstanding research is now available to read in #Oncogenesis.
▶️ Read the open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.
October 30, 2025 at 8:19 AM
Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.
Reposted by Jean-Ehrland RICCI
“SYT7 accelerates nasopharyngeal carcinoma progression via ALDH1A3-mediated STAT3 signaling activation”
🔵 Interesting research led by Xinxin Xiang has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Xinxin Xiang has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
October 30, 2025 at 8:19 AM
“SYT7 accelerates nasopharyngeal carcinoma progression via ALDH1A3-mediated STAT3 signaling activation”
🔵 Interesting research led by Xinxin Xiang has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
🔵 Interesting research led by Xinxin Xiang has been featured in #Oncogenesis.
▶️ Read the full open access article here: www.nature.com/articles/s41...
Reposted by Jean-Ehrland RICCI
Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
October 27, 2025 at 2:35 PM
Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
Reposted by Jean-Ehrland RICCI
📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀
October 27, 2025 at 2:29 PM
📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀
Reposted by Jean-Ehrland RICCI
🔬 Oncogenesis at the 6th Metabolism & Cancer Meeting 🔬
We were proud to support the 6th Metabolism & Cancer Meeting, held on 8–10 October in La Grande-Motte, France.
#CancerResearch #Metabolism #Oncogenesis #ScientificMeeting
We were proud to support the 6th Metabolism & Cancer Meeting, held on 8–10 October in La Grande-Motte, France.
#CancerResearch #Metabolism #Oncogenesis #ScientificMeeting
October 27, 2025 at 2:27 PM
🔬 Oncogenesis at the 6th Metabolism & Cancer Meeting 🔬
We were proud to support the 6th Metabolism & Cancer Meeting, held on 8–10 October in La Grande-Motte, France.
#CancerResearch #Metabolism #Oncogenesis #ScientificMeeting
We were proud to support the 6th Metabolism & Cancer Meeting, held on 8–10 October in La Grande-Motte, France.
#CancerResearch #Metabolism #Oncogenesis #ScientificMeeting
Reposted by Jean-Ehrland RICCI
Romain RISCAL (IRCM - Institut de Recherche en Cancérologie de Montpellier) et Eric Solary (Gustave Roussy, Vice‑président de la Fondation ARC pour la recherche sur le cancer).
October 22, 2025 at 9:18 AM
Romain RISCAL (IRCM - Institut de Recherche en Cancérologie de Montpellier) et Eric Solary (Gustave Roussy, Vice‑président de la Fondation ARC pour la recherche sur le cancer).
Reposted by Jean-Ehrland RICCI
Jacqueline Lehmann-Che (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Paris), Camille Lobry (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Thomas Mercher ( @gustaveroussy.fr
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)
October 22, 2025 at 9:18 AM
Jacqueline Lehmann-Che (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Paris), Camille Lobry (Institut de Recherche Saint-Louis (IRSL/UMR 1342), Thomas Mercher ( @gustaveroussy.fr
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)
Research, Villejuif), Julie Pannequin (Institut de Génomique Fonctionnelle - IGF, Montpellier)
Reposted by Jean-Ehrland RICCI
Ce matin, nous avons ouvert les 𝟐𝟗ᵉ 𝐉𝐨𝐮𝐫𝐧𝐞́𝐞𝐬 𝐉𝐞𝐮𝐧𝐞𝐬 𝐂𝐡𝐞𝐫𝐜𝐡𝐞𝐮𝐫𝐬 𝐞𝐧 𝐜𝐚𝐧𝐜𝐞́𝐫𝐨𝐥𝐨𝐠𝐢𝐞 sous le signe du partage scientifique.💡 Nous sommes fiers de soutenir cette nouvelle génération de chercheurs passionnés et audacieux.✨
#FondationARC #JournéesJeunesChercheurs #RechercheContreLeCancer #ScienceEtPartage
#FondationARC #JournéesJeunesChercheurs #RechercheContreLeCancer #ScienceEtPartage
October 22, 2025 at 9:02 AM
Ce matin, nous avons ouvert les 𝟐𝟗ᵉ 𝐉𝐨𝐮𝐫𝐧𝐞́𝐞𝐬 𝐉𝐞𝐮𝐧𝐞𝐬 𝐂𝐡𝐞𝐫𝐜𝐡𝐞𝐮𝐫𝐬 𝐞𝐧 𝐜𝐚𝐧𝐜𝐞́𝐫𝐨𝐥𝐨𝐠𝐢𝐞 sous le signe du partage scientifique.💡 Nous sommes fiers de soutenir cette nouvelle génération de chercheurs passionnés et audacieux.✨
#FondationARC #JournéesJeunesChercheurs #RechercheContreLeCancer #ScienceEtPartage
#FondationARC #JournéesJeunesChercheurs #RechercheContreLeCancer #ScienceEtPartage